000			01608 a2200445 4500
005			20250516141942.0
264		0	_c20130716
008			201307s 0 0 eng d
022			_a1873-2968
024	7		_a10.1016/j.bcp.2013.03.009 _2doi
040			_aNLM _beng _cNLM
100	1		_aBhat, Vikas K
245	0	0	_aA novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. _h[electronic resource]
260			_bBiochemical pharmacology _cJun 2013
300			_a1655-62 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAmino Acid Sequence
650	0	4	_aAnimals
650	0	4	_aBlood Glucose _xanalysis
650	0	4	_aCell Line
650	0	4	_aCricetinae
650	0	4	_aCyclic AMP _xbiosynthesis
650	0	4	_aGastric Inhibitory Polypeptide _xchemistry
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aHypoglycemic Agents _xpharmacology
650	0	4	_aInsulin _xblood
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMolecular Sequence Data
650	0	4	_aOxyntomodulin _xchemistry
650	0	4	_aPeptides _xchemistry
650	0	4	_aReceptors, Gastrointestinal Hormone _xmetabolism
650	0	4	_aReceptors, Glucagon _xmetabolism
650	0	4	_aWeight Loss _xdrug effects
700	1		_aKerr, Barry D
700	1		_aFlatt, Peter R
700	1		_aGault, Victor A
773	0		_tBiochemical pharmacology _gvol. 85 _gno. 11 _gp. 1655-62
856	4	0	_uhttps://doi.org/10.1016/j.bcp.2013.03.009 _zAvailable from publisher's website
999			_c22604305 _d22604305